NCT05203172 2026-03-18
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Pfizer
Phase 4 Recruiting
Clinical Trials
12 trialsNCT05217446 2026-03-18
SEAMARK
Pfizer
Phase 2 Active not recruiting
NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT04657991 2026-03-02
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer
Phase 3 Active not recruiting
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT04585815 2026-01-09
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Pfizer
Phase 1/2 Terminated
NCT05195632 2026-01-07
OCEANII
Pierre Fabre Medicament
Phase 2 Active not recruiting
NCT03915951 2025-11-17
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT05743036 2025-08-08
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Terminated
NCT07022457 2025-08-03
UK-EnBiRiM
Pierre Fabre Ltd
Recruiting
NCT05004350 2025-04-15
NAUTICALCRC
Pierre Fabre Medicament
Phase 2 Completed